EraCal Illustration

Investment year: 2019


Obesity and its severe comorbidities remain a major burden for the billions of affected individuals because the current anti-obesity medical therapy is unsatisfactory in terms of efficacy and safety. EraCal aims to develop proprietary first-in-class drugs to treat obesity and its comorbidities based on novel mechanism into pharmaceutical products for the world market. We identified a set of small molecules with remarkable in vivo potency and selectivity i.e. absence of side-effects in three vertebrate models.